The trial will look to evaluate and assess R327 as an intravenous dose at faster infusion rates (15 minutes and 30 minutes) across three cohorts (approximately 12 participants). Plasma and urine will be collected at various time points during and following dosing to evaluate R327’s concentrations and antibacterial effect in the urine on various bacterial strains....
If successful, this trial would be indicative of strong therapeutic potential against UTI infections (simple, complicated & recurring) across all medical treatment settings - initial stage (medical practice) and advanced stage (hospital)
First subjects expected to be dosed at Q1 2023
Hoping RCE release interim data , that should light a fire under the SP..NZT
RCE Price at posting:
58.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)